


















The MKK4 gene is selected against by inactivating 
mutations in a large number of different tumor types, 
eg, tumors of the pancreas, bile ducts, breast, colon, 
lungs, testes [1-3] at a remarkably consistent rate of 
approximately 5-10% of tumors, identifying and 
defining it, therefore, as a tumor-suppressor (or 
genome-maintenance) gene [4].   
 
Yet, experimental evidence exists that supports a pro-
oncogenic role for MKK4 [5, 6].  Finegan and Tournier 
[6], for example, recently used an inducible murine 
model of MKK4 homozygous deletion to evaluate the 
role of MKK4 in skin tumorigenesis.  They found that 
skin-specific MKK4-null mice were resistant to 
carcinogen-induced tumorigenesis.  While the paper is 
well written and the model well designed, the 
fundamental premise may well be flawed, especially 
concerning MKK4‘s role in tumorigenesis, perhaps 
misleading the line of experimentation.  There should 
be no question that MKK4 is tumor-suppressive, not 
oncogenic. MKK4 is widely selected against by tumors 
(its low rate of homozygous loss may be accounted for 
by a higher rate of heterozygous loss that could 
rationalize frequent 17p loss in diverse human 
cancers[7]) and unsurprisingly patients whose tumors 
have loss of MKK4 show statistically significant 
decrease in survival in the best controlled studies, using 
calibrated immunohistochemistry in large numbers of 
patients [8], consistent with a tumor-suppressive role. 
 
Similarly consistent with a growth-suppressive role of 
MKK4 are observations made regarding the relationship 
between MKK4 and senescence.  One of the ways 
MKK4 may suppress tumors is by inhibiting cell 
proliferation during replicative senescence,  a widely re- 
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cognized mechanism of tumor suppression.  Marasa et 
al. [9] recently observed that MKK4 abundance 
increases in senescent fibroblasts.  Overexpression of 
MKK4 decreased proliferation and promoted a 
senescent phenotype in young WI-38 human diploid 
fibroblasts and conversely, when MKK4 levels were 
lowered by several microRNAs targeting the MKK4 
mRNA, the senescent phenotype was ameliorated and 
cells proliferated more rapidly [9].  In keeping with 
these observations, human tissue from older individuals 
was observed to express higher levels of MKK4 than 
corresponding tissue from young donors [9]. 
 
In the discussion of their inducible murine model of 
MKK4 homozygous deletion, Finegan and Tournier [6] 
rightly point out that there is conflicting literature 
regarding MKK4’s role in tumorigenesis.  The reason 
for the conflicting literature is largely because MKK4 is 
difficult to study experimentally.  Their model would 
not be the first homozygous deletion model to model a 
population or a phenomenon that was not anticipated.  
For example, our own studies using homozygous 
MKK4-null cells engineered from the human pancreas 
cancer cell line PL-5 [10] showed that MKK4 deletion 
had a detrimental phenotype in a model of liver 
metastasis.  Indeed experimental human data have 
shown that when tumors experiment with MKK4-null 
states, they are successful in developing a growth 
advantage allowing them to emerge through the clonal 
selection process in only 10% of cancers having 17p 
loss.  We inferred from this observation that most tumor 
cells do not find the MKK4-null to be advantageous and 
that those PL-5 knock-out cells modeled this majority of 
cells.  One may conclude from such a line of 















  www.impactaging.com AGING, November 2010, Vol 2 N 11
   
www.impactaging.com                  752                                   AGING,    November 2010, Vol.2 No.11phenotype that was modeled offered an important 
counterweight to the selective advantage achieved by 
cells experimenting with genetic null states during 
tumorigenesis, the resultant balance determining the 
low but remarkably consistent rate of observed biallelic 
MKK4 mutations [7, 10]. 
 
Because changes effected to this gene may have 
advantageous or deleterious effects on cells depending 
on the model, cancer investigators must rely on real 
tumors and not artificial models to guide experimental 
design and interpretation such that valuable research 
time, energy, and funding are not spent studying a 
phenomenon, viz, a “pro-oncogenic” function of 
MKK4, that common cancer sense should tell us does 
not likely exist.  To put it colloquially, it does not 
matter how scientists vote regarding a pro-oncogenic or 
tumor-suppressive role of MKK4, because the tumors 
have already conducted that election in favor of the 
latter:  MKK4 must be a tumor suppressor, as concluded 
from observations on wide varieties of examined 
tumors, which uniformly present evidence of having 
selected for its loss at a consistent rate.  There is no 
convincing evidence from observations of tumor 
biology that MKK4 has any pro-oncogenic role.   
Scientists may argue for such a role, but the tumors 












and  Kern  SE.  Alterations  in  pancreatic,  biliary,  and  breast 




Kinzler  KW,  Vogelstein  B,  Lengauer  C,  and  Velculescu  VE. 
Colorectal  cancer:  mutations  in  a  signalling  pathway.  Nature. 
2005; 436: 792. 
4. Fearon ER Tumor‐Suppressor Genes. In: B. Vogelstein and K. 





6.  Finegan  KG  and  Tournier  C.  The  mitogen‐activated  protein 
kinase kinase 4 has a pro‐oncogenic role in skin cancer. Cancer 
Res. 70: 5797‐5806. 







Schulick  RD.  Mkk4  Status  Predicts  Survival  after  Resection  of 
Gastric Adenocarcinoma. Arch Surg. 2006; 141: 1095‐1099. 
9. Marasa BS, Srikantan S, Masuda K, Abdelmohsen K, Kuwano Y, 

















www.impactaging.com                  753                                   AGING,    November 2010, Vol.2 No.11